153 / 172
153
approach at the same institute. Mod Rheumatol 2011 Jul 15.
[Epub ahead of print]
79. Kiely PD, Brown AK, Edwards CJ, O'Reilly DT, Ostör AJ,
Quinn M, et al. Contemporary treatment principles for early
rheumatoid arthritis: a consensus statement. Rheumatology
(Oxford) 2009;48:765-72.
80.Mota LM, Cruz BA, Brenol CV, Pereira IA, Rezende-Fronza
LS, Bertolo MB, et al. 2012 Brazilian Society of Rheumatology
Consensus for the treatment of rheumatoid arthritis. Rev Bras
Reumatol 2012;52:152-74.
81. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie
RA, Genovese MC, et al. Rituximab for rheumatoid arthritis
refractory to anti-tumor necrosis factor therapy: Results of a
multicenter, randomized, double-blind, placebo-controlled,
phase III trial evaluating primary efficacy and safety at twenty-
four weeks. Arthritis Rheum 2006;54:2793-806.
82. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B,
Racewicz AJ, et al. Efficacy and safety of different doses and
retreatment of rituximab: a randomised, placebo-controlled
trial in patients who are biological naive with active
rheumatoid arthritis and an inadequate response to
methotrexate (Study Evaluating Rituximab's Efficacy in MTX
iNadequate rEsponders (SERENE)). Ann Rheum Dis
2010;69:1629-35.
83. Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S,
Genovese MC, et al. Rituximab inhibits structural joint damage
in patients with rheumatoid arthritis with an inadequate
response to tumour necrosis factor inhibitor therapies. Ann
Rheum Dis 2009;68:216-21.
84. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland
ML, Tarp U, et al. Highest clinical effectiveness of rituximab in
autoantibody-positive patients with rheumatoid arthritis and
in those for whom no more than one previous TNF antagonist